[go: up one dir, main page]

AU8171287A - Oral administration capsule with a nicotine-containing fluid medium - Google Patents

Oral administration capsule with a nicotine-containing fluid medium

Info

Publication number
AU8171287A
AU8171287A AU81712/87A AU8171287A AU8171287A AU 8171287 A AU8171287 A AU 8171287A AU 81712/87 A AU81712/87 A AU 81712/87A AU 8171287 A AU8171287 A AU 8171287A AU 8171287 A AU8171287 A AU 8171287A
Authority
AU
Australia
Prior art keywords
nicotine
oral administration
fluid medium
capsule
containing fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU81712/87A
Other versions
AU622101B2 (en
Inventor
Franz Adlkofer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FORSCHUNGSGESELLSCHAFT RAUCHEN und GESUNDHEIT MBH
Original Assignee
FORSCHUNGSGESELLSCHAFT RAUCHEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FORSCHUNGSGESELLSCHAFT RAUCHEN filed Critical FORSCHUNGSGESELLSCHAFT RAUCHEN
Publication of AU8171287A publication Critical patent/AU8171287A/en
Application granted granted Critical
Publication of AU622101B2 publication Critical patent/AU622101B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An oral administration capsule with a nicotine-containing, fluid medium. The capsule can be opened by pressing it with the teeth, the amount of nicotine is between 0.1 and 10 mg, the medium contains additives to improve its flavour and consistency and its pH is between 6 and 10. A capsule is thus obtained that can have various uses, especially to reduce addiction to smoking and to control feelings of hunger.
AU81712/87A 1986-11-18 1987-11-06 Oral administration capsule with a nicotine-containing fluid medium Ceased AU622101B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3639418 1986-11-18
DE19863639418 DE3639418A1 (en) 1986-11-18 1986-11-18 NICOTINE-BASED AGENT

Publications (2)

Publication Number Publication Date
AU8171287A true AU8171287A (en) 1988-06-16
AU622101B2 AU622101B2 (en) 1992-04-02

Family

ID=6314221

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81712/87A Ceased AU622101B2 (en) 1986-11-18 1987-11-06 Oral administration capsule with a nicotine-containing fluid medium

Country Status (9)

Country Link
EP (1) EP0324794B1 (en)
JP (1) JP2602043B2 (en)
CN (1) CN87107852A (en)
AT (1) ATE72114T1 (en)
AU (1) AU622101B2 (en)
BR (1) BR8707879A (en)
DE (3) DE3639418A1 (en)
DK (1) DK173353B1 (en)
WO (1) WO1988003803A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
DE4440563A1 (en) * 1994-11-12 1996-05-15 Herzog Sen Rolf Nicotine-contg. media and perfume ointments as substitute for smoking
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
AU2340397A (en) * 1996-03-21 1997-10-10 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
AUPO108596A0 (en) * 1996-07-18 1996-08-08 Collier, Gregory Treatment of obesity
US6211194B1 (en) 1998-04-30 2001-04-03 Duke University Solution containing nicotine
US6268386B1 (en) * 1998-06-25 2001-07-31 Marshall Anlauf Thompson Nicotine beverage
GB2338896B (en) * 1998-07-02 2003-05-21 Reckitt & Colmann Prod Ltd Chewable Capsules
DE60040293D1 (en) 1999-07-28 2008-10-30 Univ R USE OF NICOTIN IN THE ANGIOGENESIS AND THE VASCULOSIS
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
AT409219B (en) * 1999-08-13 2002-06-25 Red Bull Gmbh Use of nicotine for producing pharmaceuticals
SE0104388D0 (en) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
DK3473251T3 (en) 2002-12-20 2024-01-22 Niconovum Ab NICOTINE-CELLULOSE COMBINATION
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
WO2005007068A1 (en) * 2003-07-22 2005-01-27 The Kiwigel Company Limited Nicotine packaging system
NO20042835D0 (en) * 2004-07-05 2004-07-05 Nils-Erik Skeide Encapsulated tobacco smoke
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
ES2521494T3 (en) * 2007-04-02 2014-11-12 Parkinson's Institute Methods and compositions for reducing the side effects of therapeutic treatments
CN101249130B (en) * 2008-04-11 2011-06-15 桂林商源植物制品有限公司 Medicinal or health care combination for stop smoking or alleviating stop smoking syndrome
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
JP2018511355A (en) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Drug delivery method and system
JP2018511127A (en) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Craving input and support system
WO2016188932A2 (en) * 2015-05-22 2016-12-01 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Combination compositions and their use in methods for treating obesity and obesity-related disorders
CN105341990A (en) * 2015-12-16 2016-02-24 浙江中烟工业有限责任公司 An electronic cigarette liquid that enhances the physiological satisfaction of electronic cigarettes
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Device and method for transdermal drug delivery
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (en) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
US3870794A (en) * 1974-02-20 1975-03-11 Foundation For Behavioral Rese Treatment of certain emotional disorders with nicotine compounds
GB1528391A (en) * 1976-01-05 1978-10-11 Gildemeister V Aerosol compositions
DE3241437A1 (en) * 1982-11-10 1984-05-10 Ferdinand Prof. Dr.med. 6901 Wilhelmsfeld Schmidt Composition for stopping smoking and/or for intake of nicotine without side effects by addicted smokers
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
BE899037A (en) * 1984-02-29 1984-06-18 Trenker Ady Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt
DE3438284A1 (en) * 1984-10-16 1985-03-07 Hans-Harald von 2400 Lübeck Tilly Nicotine-containing depot plaster
EP0186502A3 (en) * 1984-12-25 1986-12-10 Jano Tyroler Flavor capsule and method of preparing same
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment

Also Published As

Publication number Publication date
EP0324794B1 (en) 1992-01-29
DE3645036A1 (en) 1989-01-05
BR8707879A (en) 1989-10-03
EP0324794A1 (en) 1989-07-26
WO1988003803A1 (en) 1988-06-02
CN87107852A (en) 1988-06-22
DE3639418C2 (en) 1989-08-03
JPH02501304A (en) 1990-05-10
ATE72114T1 (en) 1992-02-15
JP2602043B2 (en) 1997-04-23
DE3639418A1 (en) 1988-06-09
DK385888A (en) 1988-07-08
DK385888D0 (en) 1988-07-08
DK173353B1 (en) 2000-08-07
DE3776574D1 (en) 1992-03-12
AU622101B2 (en) 1992-04-02

Similar Documents

Publication Publication Date Title
AU8171287A (en) Oral administration capsule with a nicotine-containing fluid medium
GB1315626A (en) Substituted p-menthanes and compositions containing them
Sweet et al. The relationship of smoking to localized osteitis
EP0146334A3 (en) Chewing tobacco product
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
CA2127253A1 (en) Composition to help stop smoking
AU2989695A (en) Pharmaceutically stable oxaliplatinum preparation
AU581412B2 (en) Tobacco product
NO20054324L (en) Use of ranolazine and at least one pH-dependent binder for the preparation of ranolazine preparations with depot effect
IE882073L (en) Pediatric ibuprofen formulations
AU6609490A (en) Oral and dental hygiene preparation
CA2025545A1 (en) Processing of tobacco leaves
AU6977491A (en) Smoking substitute
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
ES2010443A6 (en) Make-your-own system for making a cigarette, especially a filter-tipped cigarette
GB1521114A (en) Method and arrangement for producing cigarettes with dense ends
GB1413177A (en) Process for the manufacture of regenerated tobacco
EP0296116A3 (en) Palatable edible oil compositions
JO1560B1 (en) Smoke mouth wash
ES398108A1 (en) Pharmaceutical composition
JPS6413019A (en) Aldose reductase inhibitor
JPS52108014A (en) Artificial saliva
GB1528786A (en) Smoking composition
GB1401824A (en) Oxidised polysaccharide
JPS53107482A (en) Preparation of 2-hydroxy-beta-ionone by microbial conversion of beta-ionone

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired